[Myelodysplastic syndromes: mechanisms of transformation and neoplastic progression and their clinical implications]

The use of peripheral-blood hematopoietic progenitors mobilized with standard-dose chemotherapy plus granulocyte-colony-stimulating factor to support multicyclic dose-intensive chemotherapy for advanced breast-cancer.

Oncology reports·2011

Advanced breast-cancer - a randomized study of different doses of epirubicin associated with fixed doses of cyclophosphamide and 5-Fluorouracil.

Oncology reports·2011

A prospective, controlled, nonrandomized study on prophylactic parenteral dichloromethylene bisphosphonate (clodronate) in multiple-myeloma.

International journal of oncology·2011

Sequential administration of interleukin-3 and granulocyte-macrophage colony-stimulating factor following intensified, accelerated CEE (cyclophosphamide, epirubicin, etoposide) chemotherapy in patients with solid tumors.

International journal of oncology·2011

Shortened and intensified MJMA: an effective salvage therapy for relapsed and refractory lymphomas and a strong mobilizer of PBSCs.

Bone marrow transplantation·2009

Lymphatic vascular density and lymphangiogenesis during tumour progression of carcinoma ex pleomorphic adenoma.

Journal of clinical pathology·2006

Autoimmune and inflammatory diseases associated with T-cell clonal expansion.

Haematologica·2026

Macrophage-specific LAMTOR2 deletion disrupts systemic iron homeostasis in mice.

Haematologica·2026

Dual inhibition of JAK and MEK suppresses T-cell acute lymphoblastic leukemia induced by mutant IL7R and RASGRP1 overexpression.

Haematologica·2026

Validation of the International Working Group 2023 response criteria for higher risk myelodysplastic syndromes/neoplasms using the International Consortium for Myelodysplastic Syndromes VALIDATE database and a randomized phase III trial.

Haematologica·2026

Preserving anthracycline-containing treatment in older patients with classical Hodgkin lymphoma: a role for liposomal doxorubicin. Comment on: "Age, anthracycline and mortality in 28,000 classic Hodgkin lymphoma patients: cohort study of a complete population".

Haematologica·2026

Mesenchymal stem cells in ribosomal insufficiency lead to aberrant osteoblastic differentiation and altered hematopoiesis.

Haematologica·2026

Catecholamine-Secreting Retroperitoneal Paraganglioma: A Case Report and Literature Review.

Case reports in urology·2026

Incidence and reasons for cancellation on the day of elective surgery: a systematic review and meta-analysis.

Anaesthesia·2026

CRISPR integration of an FLT3 CAR into the TRAC locus generates CAR T cells for AML.

Genome medicine·2026

Single-cell transcriptomics reveals transcriptional reprogramming and microenvironmental remodeling in ectopic ACTH/CRH-secreting pheochromocytomas.

Journal of translational medicine·2026

CUE domain-containing 2 promotes diffuse large B-cell lymphoma progression via PP2A-B55β degradation and shapes macrophage-mediated immune responses.

Molecular biomedicine·2026

FDXR upregulation by p63/p73 is a prognostic and therapeutic marker of adult T-cell leukemia/lymphoma.

EMBO molecular medicine·2026

Related Experiment Videos

[Myelodysplastic syndromes: mechanisms of transformation and neoplastic progression and their clinical implications]

Related Concept Videos

The use of peripheral-blood hematopoietic progenitors mobilized with standard-dose chemotherapy plus granulocyte-colony-stimulating factor to support multicyclic dose-intensive chemotherapy for advanced breast-cancer.

Advanced breast-cancer - a randomized study of different doses of epirubicin associated with fixed doses of cyclophosphamide and 5-Fluorouracil.

A prospective, controlled, nonrandomized study on prophylactic parenteral dichloromethylene bisphosphonate (clodronate) in multiple-myeloma.

Sequential administration of interleukin-3 and granulocyte-macrophage colony-stimulating factor following intensified, accelerated CEE (cyclophosphamide, epirubicin, etoposide) chemotherapy in patients with solid tumors.

Shortened and intensified MJMA: an effective salvage therapy for relapsed and refractory lymphomas and a strong mobilizer of PBSCs.

Lymphatic vascular density and lymphangiogenesis during tumour progression of carcinoma ex pleomorphic adenoma.

Autoimmune and inflammatory diseases associated with T-cell clonal expansion.

Macrophage-specific LAMTOR2 deletion disrupts systemic iron homeostasis in mice.

Dual inhibition of JAK and MEK suppresses T-cell acute lymphoblastic leukemia induced by mutant IL7R and RASGRP1 overexpression.

Validation of the International Working Group 2023 response criteria for higher risk myelodysplastic syndromes/neoplasms using the International Consortium for Myelodysplastic Syndromes VALIDATE database and a randomized phase III trial.

Preserving anthracycline-containing treatment in older patients with classical Hodgkin lymphoma: a role for liposomal doxorubicin. Comment on: "Age, anthracycline and mortality in 28,000 classic Hodgkin lymphoma patients: cohort study of a complete population".

Mesenchymal stem cells in ribosomal insufficiency lead to aberrant osteoblastic differentiation and altered hematopoiesis.

Catecholamine-Secreting Retroperitoneal Paraganglioma: A Case Report and Literature Review.

Incidence and reasons for cancellation on the day of elective surgery: a systematic review and meta-analysis.

CRISPR integration of an FLT3 CAR into the TRAC locus generates CAR T cells for AML.

Single-cell transcriptomics reveals transcriptional reprogramming and microenvironmental remodeling in ectopic ACTH/CRH-secreting pheochromocytomas.

CUE domain-containing 2 promotes diffuse large B-cell lymphoma progression via PP2A-B55β degradation and shapes macrophage-mediated immune responses.

FDXR upregulation by p63/p73 is a prognostic and therapeutic marker of adult T-cell leukemia/lymphoma.

Related Experiment Videos

[Myelodysplastic syndromes: mechanisms of transformation and neoplastic progression and their clinical implications]

Related Concept Videos

Related Articles